Considering that the standard first-line therapy for patients with advanced NSCLC is an anti-PD-1/L1 antibody in combination with platinum-based chemotherapy [78], it is plausible that KRAS G12C-mutated NSCLC patients generally receive sotorasib in the second-line setting after chemotherapy with immune checkpoint inhibitors. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.